OXITAN

OXITAN (Oxaliplatin) 5mg/ml Injection

Features

OXITAN (Oxaliplatin) is a platinum-based drug, usually classified as alkylating group.

ATC-Code: L01XA03

Mechanism of action:

OXITAN (Oxaliplatin) is an antineoplastic agent, belonging to a new class of platinum compounds that contains a platinum atom complexed with oxalate and diaminocyclohexane (DACH). It exhibits a broad spectrum of cytotoxic activity in vitro and anti-tumour activity in vivo in various tumour model systems, including models of colorectal cancer in man. Studies on the mechanism of action (though this has not been fully elucidated) show that the hydrated derivatives resulting from the biotransformation of OXITAN (Oxaliplatin) interact with DNA to form intra and inter-strand bonds, causing an interruption in DNA synthesis, which is the reason for its cytotoxic and anti-tumour activities.

Therapeutic Indications

OXITAN (Oxaliplatin) in combination with 5-fluorouracil and folinic acid is indicated:

  • For the adjuvant treatment of stage III colon cancer (Duke’s C), following complete resection of the primary tumour
  • For the treatment of metastatic colorectal cancer

Presentation

Strength is denoted by disposable cap colour. 

Strength

Packaging

Pack Size*
50 mg/10 ml 10ml clear glass vial 1
100 mg/20 ml 20ml clear glass vial 1
200 mg/40 ml 40ml clear glass bottle 1

* Not all pack sizes may be marketed or available locally.
* Product images are for illustration purposes only. 

Product Information

​Please note that this product may not be available in all countries due to different registration status. Additionally, approved indications, contraindications, side effects, warnings and all other product characteristics may differ between countries.

If you require any information, please contact your local organization.